Impact of radiation dose on patient-reported acute taste alteration in a prospective observational study cohort in head and neck squamous cell cancer (HNSCC).
Dosimetry
IMRT
Taste buds
Taste impairment
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
11
04
2023
accepted:
16
08
2023
medline:
7
12
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
Taste alteration (TA) is a frequent acute side effect of radiation treatment in HNSCC patients. Principal aim of our study was to investigate dosimetric parameters in relation to patient-assessed taste impairment in a prospective cohort treated with intensity-modulated radiotherapy. All patients with locally advanced HNSCC and amenable to radical treatment were included. Chemotherapy-induced taste alteration scale (CITAS), EORTC QLQ-C30 and QLQ-HN43 questionnaires at baseline (T0), 3 weeks (T1) and 3 months (T2) after radiotherapy conclusion were used to assess taste impairment. Base of tongue, submandibular glands (SG), parotid glands (PG) and taste buds, along with anterior and medium third of the tongue, were considered as organs at risk and thus delineated according to consensus guidelines. The mean dose to the above-mentioned structures was correlated with patient-reported outcomes. Between September 2019 and November 2020, 33 patients were recruited, 31 of which analyzed. 71% had oropharyngeal carcinoma, mostly HPV-related (60%). All were treated with tomotherapy. 77.4% had concurrent cisplatin. Mean scores of general taste alterations, global health status and dry mouth and sticky saliva were assessed. The mean doses to the anterior third, medium third and base of the tongue were 23.85, 35.50 and 47.67 Gy, respectively. Taste buds received 32.72 Gy; right and left parotid 25 and 23 Gy; right and left submandibular glands 47.8 and 39.4 Gy. At univariate analysis, dysgeusia correlated with SG mean dose (95% CI 0-0.02 p = 0.05) and PG mean dose (95% CI 0-0.02 p = 0.05); dry mouth with mean dose to anterior (95% CI 0.03-1.47 p = 0.04) and medium third (95% CI 0.02-0.93 p = 0.04) of the tongue, to taste buds (95% CI 0.06-0.96 p = 0.03) and to SGs (95% CI 0.06-0.63 p = 0.02); pain mouth with mean dose to taste buds (95% CI 0-0.02 p = 0.04), to SGs (95% CI 0-0.03 p = 0.03) and to base tongue (95% CI 0-0.02 p = 0.02). Our analysis supports the influence of dose distribution on the development of TA in HNSCC patients. The contribution of dose to taste buds and tongue subvolumes remains unclear and worthy of further investigation.
Identifiants
pubmed: 37642816
doi: 10.1007/s11547-023-01707-5
pii: 10.1007/s11547-023-01707-5
pmc: PMC10700473
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1571-1579Informations de copyright
© 2023. The Author(s).
Références
Br J Cancer Suppl. 1986;7:9-11
pubmed: 3459546
JAMA Otolaryngol Head Neck Surg. 2022 Jul 1;148(7):604-611
pubmed: 35616981
Dysphagia. 2023 Feb;38(1):159-170
pubmed: 35587295
Radiother Oncol. 2021 Apr;157:63-69
pubmed: 33217499
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):354-361
pubmed: 27473816
J Oncol. 2021 Jun 9;2021:5566508
pubmed: 34211551
Cancer Treat Rev. 2014 Oct;40(9):1106-17
pubmed: 25064135
Med Oncol. 2019 Apr 9;36(5):44
pubmed: 30968205
Front Oncol. 2020 Oct 06;10:1708
pubmed: 33117669
Strahlenther Onkol. 2008 Mar;184(3):157-62
pubmed: 18330512
Head Neck. 2006 Jun;28(6):508-16
pubmed: 16619275
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Medsurg Nurs. 2014 May-Jun;23(3):165-70, 184
pubmed: 25137792
Acta Oncol. 2022 Feb;61(2):146-152
pubmed: 35060430
Radiology. 1982 Jul;144(1):163-9
pubmed: 7089250
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1422-9
pubmed: 17084561
Radiat Oncol. 2019 Jul 29;14(1):131
pubmed: 31358029
Curr Treat Options Oncol. 2018 Nov 9;19(12):72
pubmed: 30411162
Laryngoscope. 2005 Dec;115(12):2178-82
pubmed: 16369163
Clin Transl Radiat Oncol. 2018 Feb 07;9:42-47
pubmed: 29594250
J Dent Res. 2006 Jul;85(7):608-11
pubmed: 16798859
Radiol Med. 2021 Dec;126(12):1571-1583
pubmed: 34865190
Radiol Med. 2018 Mar;123(3):217-226
pubmed: 29094268
Int J Radiat Oncol Biol Phys. 1982 Jun;8(6):991-7
pubmed: 7107441
Chem Senses. 2019 May 29;44(5):319-326
pubmed: 30957861
Radiol Med. 2017 Apr;122(4):303-308
pubmed: 28070838
Radiol Med. 2018 Jun;123(6):415-423
pubmed: 29368244
Radiother Oncol. 2015 Oct;117(1):83-90
pubmed: 26277855
Radiol Med. 2015 Aug;120(8):753-8
pubmed: 25663551
Cancer Treat Rev. 2006 Nov;32(7):541-7
pubmed: 16887272
Radiol Med. 2014 Aug;119(8):634-41
pubmed: 24424659